A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
NCT02061761
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Neoplasms
Interventions
BIOLOGICAL:
BMS-986016
BIOLOGICAL:
BMS-936558
Sponsor
Bristol-Myers Squibb